EVER Pharma gained EU-Approval for Advanced Cancer Treatment
Details : Eribulin EVER Pharma is a microtubule inhibitor which is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.
Brand Name : Eribulin EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 16, 2024
Gland Pharma Receives USFDA Approval for Eribulin Mesylate Injection
Details : Eribulin Mesylate, a non-taxane microtubule dynamics inhibitor used for the treatment of breast cancer, is expected to be the first generic approval on the market.
Brand Name : Eribulin Mesylate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 07, 2024
Kexing Introduces Eribulin Mesylate Injection, Expanding Overseas Product Offerings
Details : Under the agreement, Kexing licenses Eribulin Mesylate Injection, indicated for patients with locally advanced or metastatic breast cancer, from Xiling Lab
Brand Name : Eribulin Mesylate-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 05, 2024
Details : Halaven (eribulin mesylate) injection is indicated for the treatment of patients with metastatic breast cancer (mBC) who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease.
Brand Name : Halaven
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 01, 2022
Details : Halaven (eribulin) is a microtubule dynamics inhibitor in the halichondrin class with a novel mechanism of action, s a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai.
Brand Name : Halaven
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 11, 2022
Details : First prospective study for Evexomostat (SDX-7320) , aims to demonstrate that restoring insulin sensitivity in breast cancer patients with baseline insulin resistance will improve clinical outcomes.
Brand Name : SDX-7320
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
Lead Product(s) : Balixafortide,Eribulin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Balixafortide (POL6326) is a potent, specific, and highly selective antagonist of the chemokine receptor CXCR4, a G-protein coupled receptor (GPCR) that regulates the trafficking and homing of both cancer cells and cells of the patient’s immune system.
Brand Name : POL6326
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 28, 2021
Lead Product(s) : Balixafortide,Eribulin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Balixafortide,Eribulin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study confirmed the positive safety and tolerability profile of balixafortide in line with the previously reported Phase Ib study.
Brand Name : POL6326
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 28, 2021
Lead Product(s) : Balixafortide,Eribulin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Farletuzumab,Eribulin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Bristol Myers Squibb
Deal Size : $3,100.0 million
Deal Type : Collaboration
Details : MORAb-202, consisting of farletuzumab paired with a cathepsin B-cleavable linker and eribulin. Eisai and BMS will develop and commercialize MORAb-202 in Japan; China; countries in the Asia-Pacific region*; the U.S; Canada; Europe, including the EU and th...
Brand Name : MORAb-202
Molecule Type : Large molecule
Upfront Cash : $650.0 million
June 18, 2021
Lead Product(s) : Farletuzumab,Eribulin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Bristol Myers Squibb
Deal Size : $3,100.0 million
Deal Type : Collaboration
Lead Product(s) : Margetuximab,Capecitabine,Eribulin
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® (trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial.
Brand Name : Margenza
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 16, 2020
Lead Product(s) : Margetuximab,Capecitabine,Eribulin
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances & suspensions.
